The Optimization of Mycoplasm Pneumonia Antibiotic Therapy

Brief Title

The Optimization of Mycoplasm Pneumonia Antibiotic Therapy

Official Title

The Optimization of Mycoplasm Pneumonia Antibiotic Therapy: Multi-centre, Prospective, Randomized Controlled Study

Brief Summary

      Mycoplasma pneumoniae, an important pathogen of community acquired pneumonia,are becoming
      more and more resistant to macrolide. The study aim is to optimize anti-infection therapy.
    

Detailed Description

      Mycoplasma pneumoniae was one of important atypical pathogens of community acquired
      pneumonia. As lack of cell wall, β-lactam medicines were invalid, however, macrolides,
      tetracyclines and quinolones were effective. But from 2001, many countries reported
      macrolide- resistant Mycoplasma pneumoniae. Typically, erythromycin was first-line antibiotic
      medicine. With the resistance increasing, Mycoplasm pneumonia treatment will become more and
      more difficult. Thus, optimization of Mycoplasm pneumonia antibiotic therapy is very
      important.
    


Study Type

Interventional


Primary Outcome

Time to resolution of fever (defined as the period from start of study-drug to relief of fever)

Secondary Outcome

 Time to resolution of respiratory symptoms(defined as the period from start of study-drug to relief of symptoms)

Condition

Mycoplasma Pneumonia

Intervention

Moxifloxacin

Study Arms / Comparison Groups

 Moxifloxacin
Description:  

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

208

Start Date

October 2010

Completion Date

December 2014

Primary Completion Date

December 2014

Eligibility Criteria

        Inclusion Criteria:

          1. Confirmed community acquired pneumonia

          2. 60ys≥age≥18 ys

          3. Respiratory symptom (cough accompanied by little or no sputum)

          4. New infiltration showed by chest radiology(x-ray or CT)

          5. Lung signs was not obvious

          6. White blood cell<10,000/mm3

          7. Without underlying diseases or mild

        Exclusion Criteria:

          1. Age<18ys or >60ys

          2. Pregnancy or breast-feeding

          3. Over one week after the onset of symptoms

          4. HIV infection

          5. Recent 90-day hospitalized history(length of stay greater than 2 days)

          6. Live in nursing homes or rehabilitation hospitals

          7. Taken macrolides or quinolones medicines before enrollment
      

Gender

All

Ages

18 Years - 60 Years

Accepts Healthy Volunteers

No

Contacts

Bin Cao, Doctor, , 

Location Countries

China

Location Countries

China

Administrative Informations


NCT ID

NCT01259141

Organization ID

MP201011


Responsible Party

Principal Investigator

Study Sponsor

Capital Medical University


Study Sponsor

Bin Cao, Doctor, Study Chair, Capital Medical University affiliated Beijing Chaoyang Hospital, Beijing Respiratory Medicine Insititute


Verification Date

July 2015